Randomized Trialhigh evidence
Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
The New England journal of medicine·October 23, 2026·PMID 42912700
Why it mattersIgA nephropathy often progresses despite renin-angiotensin system blockade, and proteinuria is a key risk factor for kidney failure. Ravulizumab offers a targeted complement-inhibition approach that may address underlying glomerular inflammation, potentially improving long-term renal outcomes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled